Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator of RNA polymerase II transcription subunit 6 (MED6) is a highly conserved protein that is a core component of the Mediator complex, an essential multi-subunit coactivator that regulates transcription of nearly all RNA polymerase II-dependent genes in eukaryotes[4][7]. MED6 functions as a critical interface between the head and middle modules of Mediator, relaying regulatory signals from transcriptional activators to the core transcriptional machinery[1][5]. It is essential for conformational changes and the functioning of the Mediator complex during transcriptional activation, and its disruption impairs the postrecruitment steps of gene activation[1][3][5]. Mutations in key domains of MED6 abolish cell viability in model organisms, highlighting its importance in gene expression regulation. While MED6 has aliases linked to cancer antigens (e.g., NY-REN-28), current data suggest it is fundamentally a structural and regulatory transcriptional coactivator, not a direct druggable target or receptor[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator of RNA polymerase II transcription subunit 6 (MED6).